Synopsis: Nephrocare Health Services Limited (NephroPlus) has strengthened its international footprint through the acquisition of a dialysis centre in Paranaque City, Philippines. The move comes after a strong FY26 performance that saw revenue approach ₹1,000 crore, net profit surge nearly 75%, and international operations contribute 42% of total revenue, reinforcing the company’s strategy of building a leading global dialysis network.
Shares of Nephrocare Health Services Limited (trading under ticker NEPHROPLUS, Scrip Code: 544647), with a market capitalization of Rs. 7,088.57 crore, were trading at Rs. 706.45, up 0.06% from their previous closing price of Rs. 706.00. The stock touched an intraday high of Rs. 741.25 and a low of Rs. 706.45. It is currently trading at a consolidated P/E ratio of 113.22.
According to the filing, Nephrocare Health Care Services, Philippines Inc., an overseas step-down wholly owned subsidiary of the company, signed an Asset Transfer Agreement on June 9, 2026, with Amica Healthcare System Corporation to acquire selected assets of a dialysis centre located in Dona Soledad, Don Bosco, Paranaque City, Philippines.
The transaction value stands at PhP 32.64 million (Philippine Pesos Thirty-Two Million Six Hundred Forty Thousand), equivalent to approximately ₹5.06 crore based on prevailing exchange rates.
Strengthening Presence in a High-Growth Healthcare Market
The acquisition forms part of NephroPlus’ strategy of expanding through targeted asset acquisitions rather than relying solely on greenfield projects. By acquiring an operational dialysis centre, the company gains access to existing infrastructure, regulatory approvals, and potentially an established patient base, enabling faster revenue generation and lower execution risk.
Paranaque City, located within Metro Manila, is a densely populated urban region with growing demand for dialysis services. Rising cases of diabetes and hypertension across the Philippines continue to drive chronic kidney disease incidence, creating significant long-term demand for specialized renal care.
The transaction is structured as a straightforward asset acquisition and does not involve any special rights, board representation, capital structure restrictions, or shareholding preferences. The company also confirmed that Amica Healthcare System Corporation is not related to NephroPlus, its promoters, or promoter group, and the transaction does not qualify as a related-party deal.
Strong FY26 Performance Provides Growth Momentum
The Philippines acquisition comes on the back of a standout FY26 performance, highlighting the company’s growing scale and improving profitability. For FY26, consolidated revenue from operations increased 32.2% year-on-year to ₹998.8 crore, bringing the company close to the ₹1,000 crore milestone. Net profit surged 74.6% to ₹128.3 crore, reflecting strong operating leverage across the business.
The company also reported improved operating efficiency. Adjusted EBITDA margins expanded to 23.8% from 22.9% in FY25, supported by higher revenue per treatment, which increased 13.3% to ₹2,598.
A key highlight was the increasing contribution from international markets. Overseas operations accounted for approximately 42% of total revenue during FY26, compared with around 32% in the previous year, demonstrating the growing importance of the company’s global business.
Building a Global Dialysis Network
The Paranaque City acquisition adds to an already rapidly expanding international platform. As of early June 2026, NephroPlus operates more than 520 dialysis clinics globally, making it one of the largest dialysis care providers worldwide. The company’s presence now spans five countries: India, the Philippines, Saudi Arabia, Uzbekistan, and Nepal.
Management has outlined ambitious expansion plans to further strengthen its market position. The company aims to add 40–50 new clinics annually in India while also expanding aggressively in the Philippines with plans to add another 15 – 16 clinics every year. These initiatives are expected to support NephroPlus’ goal of reinforcing its position as the world’s fifth-largest dialysis network
The company’s international ambitions continue to evolve beyond its existing markets. In May 2026, NephroPlus incorporated a new subsidiary in Kazakhstan, signaling its intention to expand into the Eurasian Economic Union (EAEU) region and establish a foothold in additional high-growth healthcare markets.
Alongside geographic expansion, the company is investing in technology-led healthcare delivery. NephroPlus is currently implementing its Reformmed.AI platform across its network to improve clinical outcomes, optimize treatment quality, and enhance operational efficiency.
Philippines Remains a Long-Term Opportunity
The Philippines continues to represent an attractive growth market for dialysis service providers due to a combination of rising patient volumes and relatively limited treatment infrastructure.
Many regions still face shortages of dialysis centres, creating a significant gap between demand and available capacity. NephroPlus has historically built its business by expanding into underserved markets, and the company’s approach in the Philippines appears to follow a similar strategy.
The acquisition may be modest in size at approximately ₹5.06 crore, but it demonstrates management’s willingness to deploy capital strategically to accelerate market penetration and strengthen its presence in key international geographies.
Company Overview
Nephrocare Health Services Limited, popularly known through its NephroPlus brand, is India’s largest organized dialysis network. Headquartered in Hyderabad, Telangana, the company provides haemodialysis, peritoneal dialysis, and related renal care services through an extensive network of clinics across India and international markets. The company continues to expand its presence through a combination of organic growth, strategic acquisitions, and technology-driven healthcare solutions.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies ontradebrains.inare their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post NephroPlus Acquires Philippines Dialysis Center to Anchor Global Network Scale appeared first on Trade Brains.
Original Article
(Disclaimer – This post is auto-fetched from publicly available RSS feeds. Original source: Tradebrains. All rights belong to the respective publisher.)
